Compare Travere Therapeutics Inc. Common Stock (TVTX) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs UBS Group AG Registered Ordinary Shares — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while UBS Group AG Registered Ordinary Shares trades at $46.9 (market cap $147.14B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 30.2× Travere Therapeutics Inc. Common Stock's market cap, and UBS Group AG Registered Ordinary Shares pays a 2.3% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and UBS Group AG Registered Ordinary Shares for 3 Days on average.
| TVTX | UBS | |
|---|---|---|
Market Cap | $4.88B | $147.14B |
Volume | 1,668,577 | 1,589,541 |
Sector | Health | Financials |
52-Week High | $67.52 | $55.72 |
52-Week Low | $26.79 | $36.41 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $5.01B | $315.77B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
UBS trades at $47.85, showing minimal daily movement with a 0.06% gain. The technical picture is bearish with mixed earnings performance - beating estimates in Q1 2026 but missing in Q4 2025 and Q2 2026. Analyst sentiment leans positive with 55% buy ratings, though the consensus price target of $23.57 sits well below current levels. Recent news highlights UBS's strategic focus on US expansion and ongoing integration challenges.
The outlook remains cautious given the bearish technical signals and valuation concerns. Investment opportunity exists in the company's improving profitability and revenue growth trajectory, but risks include integration challenges from recent acquisitions and exposure to European debt market volatility. The significant gap between current price and analyst targets warrants careful consideration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
